DCC-3009

Small molecule

DDeciphera Pharmaceuticals, LLC

DCC-3009 is one of 54 small molecule programs targeting Gastrointestinal Stromal Tumor. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal Stromal TumorActive, not recruiting

Gastrointestinal Stromal TumorPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Gastrointestinal Stromal Tumor

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

7 2

Avastin

BBio-Thera Solutions

Phase 3

1 3

Luye

Ascentage Pharma Group Inc.

Votrient

4 5

Yervoy

Bristol-Myers Squibb

Phase 2

2 6

TKI258

Novartis

Phase 2

2 7

Opdivo

Bristol-Myers Squibb

Phase 2

2 8

Tecentriq

Roche

Phase 2

1 9

Mekinist

Novartis

Phase 2

1 10

Lenvima

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Gastrointestinal Stromal Tumor

NCT06630234

Clinical

Trials by Indication[1]

Gastrointestinal Stromal Tumor1 trial

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Recruiting·DDeciphera Pharmaceuticals, LLC·Phase 1/2·NCT06630234·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DCC-3009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DCC-3009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DCC-3009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Deciphera Pharmaceuticals, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: DDeciphera Pharmaceuticals, LLC

DCC-3009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Gastrointestinal Stromal Tumor1 trial

References

Drug Info

Quick Facts

Related News